CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Panobinostat Nanoparticle Formulation MTX110 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03566199
NCT03566199Phase 2Completed
CompareCT.gov

An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy

Sabine Mueller, MD, PhD·interventional·Posted Jun 25, 2018·Updated Feb 25, 2022

In Brief

A Phase 2 clinical trial evaluating Panobinostat Nanoparticle Formulation MTX110 and Convection-Enhanced Delivery (CED) for Diffuse Intrinsic Pontine Glioma. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Intrinsic Pontine Glioma
CountriesUnited States
CollaboratorsMidatech Pharma US Inc., Pacific Pediatric Neuro-Oncology Consortium

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 25, 2018
Enrollment StartMay 22, 2018
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.0 years ago

Interventions

Panobinostat Nanoparticle Formulation MTX110drug

Given IT

Convection-Enhanced Delivery (CED)drug

Undergo CED